PD-Co-002

PD-Co-002 is a preclinical peptide therapeutic candidate developed by Chengdu Peide Biopharmaceutical for the treatment of chronic obstructive pulmonary disease (COPD). As of 2024, the program is in the lead optimization or pre-clinical candidate (PCC) selection stage. The drug leverages Chengdu Peide's proprietary long-acting peptide technology platform, which aims to improve the pharmacokinetic profile and therapeutic efficacy of peptide-based medicines. While the specific biological target of PD-Co-002 has not been publicly disclosed, it is designed to address the chronic inflammatory and obstructive components of COPD.